Cyclacel pharmaceuticals announces that kenneth m. ferguson, ph.d.

Berkeley heights, n.j., june 22, 2022 (globe newswire) -- cyclacel pharmaceuticals, inc. (nasdaq: cycc, nasdaq: cyccp; "cyclacel" or the "company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the election of kenneth m. ferguson, ph.d., to its board of directors. dr. ferguson was elected by and will represent the 6% convertible exchangeable preferred stockholders.
CYCC Ratings Summary
CYCC Quant Ranking